AGIOS PHARMACEUTICALS, INC. Preferred Stock Dividends, Income Statement Impact
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Preferred Stock Dividends, Income Statement Impact of $4.16 million for the 12-month period ending 2013-12-31, per its 10-K filed 2016-02-26.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2016-02-26
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2013-12-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2013-09-30 was $567.00K.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2013-06-30 was $1.80M, a 0.00% change year-over-year.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for the quarter ending 2013-03-31 was $1.80M.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for fiscal 2013 was $4.16M, a 42.11% decline from fiscal 2012.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for fiscal 2012 was $7.19M, a 131.94% increase from fiscal 2011.
- AGIOS PHARMACEUTICALS, INC. preferred stock dividends, income statement impact for fiscal 2011 was $3.10M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 3 month as first filed | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 9 month as first filed | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $567.00K derived: sum of 2 quarters · filed 2016-02-26 | $2.37M derived: sum of 3 quarters · filed 2016-02-26 | $4.16M 10-K · filed 2016-02-26 | ||
| 2013-09-30 | $567.00K 10-Q · filed 2014-11-07 | -$567.00K 10-Q · filed 2013-11-07 | $2.37M derived: sum of 2 quarters · filed 2014-11-07 | $4.16M 10-Q · filed 2014-11-07 | -$4.16M 10-Q · filed 2013-11-07 | $16.75M derived: sum of 4 quarters · filed 2015-02-24 |
| 2013-06-30 | $1.80M 10-Q · filed 2014-08-07 | $3.60M 10-Q · filed 2014-08-07 | $16.18M derived: sum of 3 quarters · filed 2015-02-24 | $14.38M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-03-31 | $1.80M 10-Q · filed 2014-05-09 | $14.38M derived: sum of 2 quarters · filed 2015-02-24 | $12.58M derived: sum of 3 quarters · filed 2015-02-24 | $14.38M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2012-12-31 | $12.58M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $10.79M derived: sum of 2 quarters · filed 2015-02-24 | $12.58M derived: sum of 3 quarters · filed 2015-02-24 | $7.19M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | -$1.80M 10-Q · filed 2013-11-07 | $0.00 derived: sum of 2 quarters · filed 2013-11-07 | -$5.39M 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | $1.80M 10-Q · filed 2013-09-05 | $3.60M 10-Q · filed 2013-09-05 | ||||
| 2011-12-31 | $3.10M 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |